Publication

Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches

Downloadable Content

Persistent URL
Last modified
  • 05/15/2025
Type of Material
Authors
    Mirko Paiardini, Emory UniversityKavita Dhodapkar, Emory UniversityJustin Harper, Emory UniversitySteven G. Deeks, University of California San FranciscoRafi Ahmed, Emory University
Language
  • English
Date
  • 2020-03-31
Publisher
  • Frontiers Media S.A.
Publication Version
Copyright Statement
  • © 2020 Paiardini, Dhodapkar, Harper, Deeks and Ahmed.
License
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 11
Start Page
  • 519
End Page
  • 519
Grant/Funding Information
  • None declared
Abstract
  • Although modern anti-retroviral therapy (ART) permits near-normal life expectancies by suppressing viral replication to clinically undetectable levels in people living with HIV (PLWH) (1), sustained treatment is complicated by complex pharmacological (i.e., adverse events, adherence, resistance) and societal issues (i.e., stigma, cost burden, medical access). Furthermore, ART is incapable of eliminating the latent viral reservoir, which is responsible for recrudescence when therapy is interrupted (2–5). Viral persistence is facilitated by a variety of mechanisms such as the exhaustion of HIV-specific cytolytic T-cells (CTLs) driven by chronic inflammation (6–8); epigenetic modifications to dampen the expression of viral proteins allowing evasion of immunosurveillance (9, 10); the localization of infected cells within immune privileged anatomical sites (11–13); and the survival of long-lived, virus-harboring cells allowing reservoir expansion via homeostatic proliferation (14, 15).
Author Notes
Keywords
Research Categories
  • Biology, Cell
  • Biology, Microbiology
  • Health Sciences, Oncology
  • Health Sciences, Immunology

Tools

Relations

In Collection:

Items